ACADIA Pharmaceuticals (STU:DR6) ROCE % : 11.96% (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ACADIA Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was 11.96%.

ACADIA Pharmaceuticals ROCE % Historical Data

The historical data trend for ACADIA Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals ROCE % Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.87

-39.47

-27.66

-43.48

-15.12

ACADIA Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-47.73	2.73	-53.07	30.16	11.96

ACADIA Pharmaceuticals ROCE % Calculation

ACADIA Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-67.289	/	( ( (554.895 - 118.595)	+	(686.793 - 233.151) )	/ 2 )
	=	-67.289	/	( (436.3	+	453.642)	/ 2 )
	=	-67.289	/	444.971
	=	-15.12 %

ACADIA Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	55.972	/	( ( (686.793 - 233.151)	+	(786.695 - 304.149) )	/ 2 )
	=	55.972	/	( ( 453.642	+	482.546 )	/ 2 )
	=	55.972	/	468.094
	=	11.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

ACADIA Pharmaceuticals (STU:DR6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ACADIA Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (STU:DR6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (STU:DR6) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ACAD:USA DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (STU:DR6) Headlines

No Headlines